Fundamental Analysis of CI
The Cigna Group, a global health insurance and services company, presents a compelling investment case characterized by strong operational performance and a robust business model. With a market cap of approximately $74.6 billion and a stock price of $282.49, Cigna trades at attractive valuations relative to its earnings and cash flows. The TTM price-to-earnings ratio stands at 11.65, significantly below the broader market, and the price-to-free-cash-flow ratio is 8.19, indicating substantial cash generation. The company's revenue per share is $1,069.78, reflecting its large scale, while net margin is 2.3% and operating margin is 3.5%, demonstrating solid profitability despite the competitive landscape. Return on equity (ROE) is 15.2% and return on assets (ROA) is 4.1%, showing efficient use of capital. The company's beta of 0.306 suggests lower volatility compared to the market, appealing to risk-averse investors. The current ratio of 0.846 and quick ratio of 0.741 indicate potential liquidity concerns, but the debt-to-equity ratio of 0.748 is manageable, and interest coverage of 7.0 provides comfort. The dividend yield is 2.2% with a payout ratio of 25.3%, leaving ample room for growth and reinvestment. The EV/EBITDA multiple of 8.51 is reasonable, and free cash flow yield is 12.2%, underscoring strong cash generation. The company operates through two primary segments: Evernorth, offering pharmacy benefits and health solutions, and Cigna Healthcare, providing a wide range of insurance products, including Medicare and individual plans. With $274.9 billion in total revenues and a wide economic moat, Cigna benefits from scale, diversified revenue streams, and a dual-engine model. The company has also been proactive in managing costs and has a history of strategic initiatives, including a recent settlement to resolve legal issues. Overall, Cigna exhibits a solid fundamental profile, but investors should monitor industry risks and regulatory changes.
